HDAC9 and cancer: Suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor used clinically for the treatment of cancer causes the dissociation of ING2 from the Sin3 deacetylase complex leading to de-repression of downstream genes and growth inhibition[47].